Wells Fargo & Company Pharma Cyte Biotech, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.01 - $2.34 $4 - $4	2 Added 3.77%	55 $0
Q3 2023 Nov 13, 2023	SELL	$2.09 - $2.89 $275 - $381	-132 Reduced 71.35%	53 $0
Q2 2023 Aug 15, 2023	BUY	$2.74 - $3.18 $153 - $178	56 Added 43.41%	185 $0
Q1 2023 May 12, 2023	SELL	$2.83 - $3.03 $33 - $36	-12 Reduced 8.51%	129 $0
Q4 2022 Feb 13, 2023	BUY	$2.39 - $3.07 $7 - $9	3 Added 2.17%	141 $0
Q3 2022 Nov 14, 2022	SELL	$2.24 - $2.85 $2 - $2	-1 Reduced 0.72%	138 $0
Q2 2022 Aug 12, 2022	BUY	$1.99 - $2.33 $21 - $25	11 Added 8.59%	139 $0
Q1 2022 May 16, 2022	BUY	$1.91 - $2.77 $1 - $2	1 Added 0.79%	128 $0
Q4 2021 Feb 14, 2022	BUY	$2.4 - $3.19 $242 - $322	101 Added 388.46%	127 $0
Q3 2021 Nov 15, 2021	BUY	$2.28 - $16.9 $59 - $439	26 New	26 $0

932K

Ticker PMCB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,750,100
Market Cap $35.1M
Description
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.